NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 6.6% – Here’s Why

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price traded down 6.6% on Monday . The company traded as low as $0.6701 and last traded at $0.6870. 297,758 shares changed hands during trading, an increase of 140% from the average session volume of 123,877 shares. The stock had previously closed at $0.7352.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Roth Mkm started coverage on shares of NeuroSense Therapeutics in a research note on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Performance

The firm has a market cap of $22.37 million, a PE ratio of -1.27 and a beta of 1.56. The stock’s 50 day simple moving average is $0.78 and its 200 day simple moving average is $0.86.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors have recently made changes to their positions in NRSN. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics in the 2nd quarter valued at $54,000. Squarepoint Ops LLC boosted its stake in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics in the 3rd quarter valued at $26,000. Finally, Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics in the 4th quarter valued at $77,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.